Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland

by Zacks Equity Research

Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.

Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (VRTX) Outperforming Other Medical Stocks This Year?

Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M

by Zacks Equity Research

Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.

Ekta Bagri headshot

Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More

by Ekta Bagri

Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.

Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) closed at $178.98 in the latest trading session, marking a +0.36% move from the prior day.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Moving Average Crossover Alert: Vertex Pharmaceuticals

by Zacks Equity Research

Vertex Pharmaceuticals Incorporated (VRTX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (VRTX) Outperforming Other Medical Stocks This Year?

The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More

by Zacks Equity Research

Key highlights of the past week include drug approvals, and other regulatory and pipeline news.

Surging Earnings Estimates Signal Upside for Vertex (VRTX) Stock

by Zacks Equity Research

Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

by Zacks Equity Research

Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

Kalyan Nandy headshot

Top Research Reports: Amazon, Caterpillar, Vertex & More

by Kalyan Nandy

Today's Research Daily features updated research reports on 12 major stocks, including Amazon (AMZN), Caterpillar (CAT) and Vertex (VRTX).

Mergers & Acquisitions Take Center Stage in Biotech Industry

by Zacks Equity Research

Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.

Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up

by Zacks Equity Research

Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.

Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up

by Zacks Equity Research

Perrigo (PRGO) reports encouraging second-quarter 2019 results. The Rx segment recovers on strong new product sales.

Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research

Celldex (CLDX) reports mixed second-quarter results. Revenues fall on reduced collaboration and contract revenues.

Is Vertex (VRTX) a Great Growth Stock?

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).

Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (VRTX) Outperforming Other Medical Stocks This Year?

Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View

by Zacks Equity Research

Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.

Proteostasis (PTI) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors will focus on the cystic fibrosis studies, when Proteostasis (PTI) reports second-quarter 2019 earnings.

Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 22.33% and 6.52%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VRTX) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.

Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded

by Zacks Equity Research

Key highlights of the past week include earnings update, collaborations and other pipeline news.

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.